Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Meletios Α. Dimopoulos(Korea University), Pieter Sonneveld(Erasmus MC Cancer Institute), Barbara Rosettani(National and Kapodistrian University of Athens), Katja Weisel(Universität Hamburg), Shona Collins(National and Kapodistrian University of Athens), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Javier de la Rubia(Universitat de València), Barbara Gamberi(University of Modena and Reggio Emilia), Antonio Ardizzoia(Alessandro Manzoni Hospital), Matthew Streetly(King's College - North Carolina), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Massimo Offidani(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Frank Bridoux(Université de Poitiers), Elisabeth Kueenburg(National and Kapodistrian University of Athens), Yan Li(The University of Texas MD Anderson Cancer Center), Pamela Bacon(National and Kapodistrian University of Athens), Antonia Di Micco(National and Kapodistrian University of Athens)
Cited by 71
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k